Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court’s Pro-Pharma Decision On Sales Rep Overtime Reproves Informal Agency Policymaking

This article was originally published in The Pink Sheet Daily

Executive Summary

Court rules that reps’ nonbinding commitments from physicians to prescribe drugs constitute a sale and thus make them outside sales employees who are exempt from overtime. Court also rebukes Labor Department’s policy change outside of rulemaking.

You may also be interested in...



White House Advances War On 'Guidance'; FDA Not Target, But May Feel Ripple Effects

US FDA's efforts to enforce against regenerative medicine and other gray market products might be collateral damage in Trump administration's latest attack on the perceived abuse of powers by regulatory agencies.

Supreme Court Attacks Dept. of Labor Actions In Sales Rep Overtime Case

The high court questioned the nature of pharmaceutical sales rep work and what constitutes a sale in the case Christopher v. SmithKline Beecham; Justice Stephen Breyer asked GSK’s attorney what the court should say in crafting an opinion.

Novartis Settles Sales Rep Overtime Suit Rather Than Await Supreme Court Ruling

Novartis agrees to pay $99 million to resolve a class action on behalf of 7,700 current and former sales representatives. The company changed the duties of its reps and cut their work hours after the suit was filed.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel